Polymorphisms inXPD,XPCand the risk of death in patients with urinary bladder neoplasms

Abstract

Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms, Acta Oncologica, 46:1, 31-41,

Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

“…[32] recurrence risk and cancer-specific survival [20]. These findings may have important clinical implications for predicting BCG response.…”

“…Other studies have also shown NER genes including XPD to be associated with Individuals with variant XPD haplotypes were more susceptible to bladder cancer. The effect was magnified when smoking was considered [24] Bladder cancer Sweden Patients carrying the variant allele of XPD (K751Q) polymorphism were at lower risk of death than the noncarriers [20] Bladder cancer Japanese Combined genotypes with at least one variant allele in XPD or XRCC1 were significantly associated with improved cancer-specific survival compared with remaining groups [25] Cancer (A metaanalysis study)…”

Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai

“…GarciaClosas et al [14] reported that subjects carrying the heterozygous XPC Lys939Gln genotype were at a significantly higher risk of developing bladder cancer. Sanyal et al reported that homozygotes for the 939Gln allele were found to significantly increase the risk of bladder cancer [13,15]. Chen et al [16] reported that attenuated expression of XPC is associated with critical events in human bladder cancer carcinogenesis and progression.…”

“…There are numerous case-control studies on XPC Lys939Gln and its role in urinary bladder cancer susceptibility [13]. GarciaClosas et al [14] reported that subjects carrying the heterozygous XPC Lys939Gln genotype were at a significantly higher risk of developing bladder cancer.…”

Meta-analysis demonstrates no association between XRCC1 Arg399Gln polymorphism and bladder cancer risk

“…Sanyal et al (2007) indicated that variant allele carriers of the XRCC1 polymorphism showed a lower risk of recurrence (Stage TaG2; P = 0.05) and death (Stage T2 or greater; P = 0.03) after instillation and radiotherapy compared to non-carriers. Sakano et al (2006) showed that for patients with bladder cancer after platinum-based chemoradiotherapy, combined genotypes with at least one variant allele in XRCC1 were significantly associated with improved cancer-specific survival compared with the remaining groups.…”